Clinical decision making using ovarian cancer risk assessment

American Journal of Roentgenology

Volumn 194, Issue 2, 2010, Pages 337-342

  Stany, Michael P ^a   Larry Maxwell, G ^a   Rose, G Scott ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

CA 125 level; Ovarian cancer; Risk assessment; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

BLOOD LEVEL; CANCER MORPHOLOGY; CANCER SURGERY; CARCINOGENESIS; CLINICAL DECISION MAKING; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; FAMILY HISTORY; HISTORY; HISTORY OF MEDICINE; HUMAN; MALIGNANT TRANSFORMATION; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TRANSVAGINAL ECHOGRAPHY;

CA-125 ANTIGEN; DECISION MAKING; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL HISTORY TAKING; OVARIAN NEOPLASMS; PHYSICAL EXAMINATION; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 76149137210     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3669     Document Type: Review

References (44)

1. DiSaia PJ, Creasman WT. Clinical gynecologic oncology, 7th ed. St. Louis, MO: Mosby, 2007
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
3. Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004; 100:1045-1052
4. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102:432-439
5. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005; 112:857-865
6. Lurie G, Thompson PJ, McDuffie KE, Carney ME, Goodman MT. Prediagnostic symptoms of ovarian carcinoma: a case-control study. Gynecol Oncol 2009; 114:231-236
7. Lowe KA, Andersen MR, Urban N, Paley P, Dresher CW, Goff BA. The temporal stability of the symptom index among women at high-risk for ovarian cancer. Gynecol Oncol 2009; 114:225-230
8. Hoskins WJ. Principles and practice of gynecologic oncology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:xix, 1419
9. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990; 50:7415-7421
10. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94:32-38
11. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117:128-139
12. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184-1203
13. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191:733-740
14. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002; 156:363-373
15. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80:708-714
16. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA 1993; 270:2813-2818
17. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004; 83:783-795
18. American College of Obstetricians and Gynecologists (ACOG), ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113:957-966
19. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130
20. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-646
21. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005; 96:222-226
22. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 89: elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008; 111:231-241
23. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60:496-504
24. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-1408
25. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80:700-707
26. Jacobs I, Bast RC Jr. The CA-125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1-12
27. Ghaemmaghami F, Karimi Zarchi M, Hamedi B. High levels of CA-125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 2007; 276:559-561
28. American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol Oncol 2002; 87:237-239
29. Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA-125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159:341-346
30. Spanos WJ. Preoperative hormonal therapy of cystic adnexal masses. Am J Obstet Gynecol 1973; 116:551-556
31. Bennington JL, Ferguson BR, Haber SL. Incidence and relative frequency of benign and malignant ovarian neoplasms. Obstet Gynecol 1968; 32:627-632
32. Dorum A, Blom GP, Ekerhovd E, Granberg S. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol 2005; 192:48-54
33. Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol 2003; 22:284-289
34. Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 1998; 69:3-7
35. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594-599
36. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77:350-356
37. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113:384-394
38. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA-125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97:922-929
39. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841-848
40. Clayton RD, Snowden S, Weston MJ, Mogensen O, Eastaugh J, Lane G. Neural networks in the diagnosis of malignant ovarian tumours. Br J Obstet Gynaecol 1999; 106:1078-1082
41. Moszynski R, Szpurek D, Smolen A, Sajdak S. Comparison of diagnostic usefulness of predictive models in preliminary differentiation of adnexal masses. Int J Gynecol Cancer 2006; 16:45-51
42. Szpurek D, Moszynski R, Smolen A, Sajdak S. Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses. Int J Gynaecol Obstet 2005; 89:108-113
43. Van Calster B, Timmerman D, Lu C, et al. Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods. Ultrasound Obstet Gynecol 2007; 29:496-504
44. van Nagell JR, DePriest PD. Management of adnexal masses in postmenopausal women. Am J Obstet Gynecol 2005; 193:30-35